Celularity Inc. (CELU)Healthcare | Biotechnology | Florham Park, United States | NasdaqCM
0.76 USD
+0.01
(1.985%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 0.76 |
Hot Take ↕ | July 11, 2026, 3:05 a.m. EDT
The investment case for Celularity is effectively broken by a catastrophic multi-year decline in business value. Over the last five years, the stock has lost 98% of its value, driven by four consecutive years of negative annual returns. This is not a temporary correction; it is a structural implosion where the market has repeatedly reassessed the company's prospects downward. Fundamentally, the picture is dire: revenue has collapsed by nearly 78% year-over-year, operating margins are deeply negative at -492%, and the balance sheet is compromised with debt significantly exceeding cash reserves. The negative book value and negative return on assets confirm that the company is currently destroying shareholder capital. While the recent price action shows some volatility, the underlying fundamentals offer no support for a recovery. With no dividend to provide income and a trajectory that suggests the core business model is failing, this security represents a severe value trap where the low price reflects the reality of deteriorating operations rather than a margin of safety. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.291555 |
| AutoTheta | 0.310601 |
| MSTL_32 | 0.393648 |
| AutoETS | 0.415769 |
| MSTL | 0.418694 |
| MSTL_32_115 | 0.425528 |
| MSTL_115 | 0.437048 |
Forecast horizon: 60 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 3.49 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.417 |
| Excess Kurtosis | -0.78 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 1.037 |
| Market Cap | 21,857,094 |
| Forward P/E | -1.32 |
| Beta | 0.54 |
| Previous Name | GX Acquisition Corp. |
| Website | https://www.celularity.com |
As of July 11, 2026, 3:05 a.m. EDT: Speculator positioning is extremely thin and fragmented, offering no clear directional signal. Call volume is negligible across all expirations, while put activity is concentrated entirely in the November 2026 expiration, suggesting a specific, low-cost hedge against a potential drop rather than a broad bearish bet. Implied volatility is elevated for near-term puts relative to calls, indicating fear of a downside event, but the lack of significant open interest or volume prevents this from being interpreted as a strong institutional or retail consensus.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.66964287 |
| Address1 | 170 Park Avenue |
| All Time High | 134.0 |
| All Time Low | 0.56 |
| Ask | 0.7684 |
| Ask Size | 5 |
| Audit Risk | 10 |
| Average Daily Volume10 Day | 168,390 |
| Average Daily Volume3 Month | 157,049 |
| Average Volume | 157,049 |
| Average Volume10Days | 168,390 |
| Beta | 0.538 |
| Bid | 1.02 |
| Bid Size | 5 |
| Board Risk | 10 |
| Book Value | -1.32 |
| City | Florham Park |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.7551 |
| Current Ratio | 0.153 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 0.8 |
| Day Low | 0.74 |
| Display Name | Celularity |
| Earnings Timestamp End | 1,755,547,200 |
| Earnings Timestamp Start | 1,755,547,200 |
| Ebitda | -54,013,000 |
| Ebitda Margins | -2.03439 |
| Enterprise To Ebitda | -1.679 |
| Enterprise To Revenue | 3.416 |
| Enterprise Value | 90,695,096 |
| Eps Forward | -0.57 |
| Eps Trailing Twelve Months | -3.66 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.817 |
| Fifty Day Average Change | -0.06189996 |
| Fifty Day Average Change Percent | -0.07576495 |
| Fifty Two Week Change Percent | -66.96429 |
| Fifty Two Week High | 4.35 |
| Fifty Two Week High Change | -3.5949 |
| Fifty Two Week High Change Percent | -0.8264138 |
| Fifty Two Week Low | 0.56 |
| Fifty Two Week Low Change | 0.19510001 |
| Fifty Two Week Low Change Percent | 0.34839287 |
| Fifty Two Week Range | 0.56 - 4.35 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,565,271,000,000 |
| Float Shares | 18,869,004 |
| Forward Eps | -0.57 |
| Forward P E | -1.3247368 |
| Free Cashflow | 5,384,625 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 115 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.24392 |
| Gross Profits | 6,476,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.37182 |
| Held Percent Institutions | 0.12774 |
| Implied Shares Outstanding | 28,945,961 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,709,164,800 |
| Last Split Factor | 1:10 |
| Long Business Summary | Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating multiple sclerosis, rheumatoid arthritis, stroke, and diabetic peripheral neuropathy. The company also produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey. |
| Long Name | Celularity Inc. |
| Market | us_market |
| Market Cap | 21,857,094 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_408304689 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | -91,800,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 21,498,165 |
| Open | 0.74 |
| Operating Cashflow | -13,254,000 |
| Operating Margins | -4.92154 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 908 768 2170 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 0.7551 |
| Post Market Time | 1,783,973,404 |
| Prev Name | GX Acquisition Corp. |
| Previous Close | 0.7404 |
| Price Hint | 4 |
| Price To Book | -0.57204545 |
| Price To Sales Trailing12 Months | 0.8232427 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.135 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0147 |
| Regular Market Change Percent | 1.98541 |
| Regular Market Day High | 0.8 |
| Regular Market Day Low | 0.74 |
| Regular Market Day Range | 0.74 - 0.8 |
| Regular Market Open | 0.74 |
| Regular Market Previous Close | 0.7404 |
| Regular Market Price | 0.7551 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 57,874 |
| Return On Assets | -0.30934998 |
| Revenue Growth | -0.774 |
| Revenue Per Share | 1.037 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 28,945,961 |
| Shares Percent Shares Out | 0.0143 |
| Shares Short | 413,401 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 345,339 |
| Short Name | Celularity Inc. |
| Short Percent Of Float | 0.0621 |
| Short Ratio | 2.77 |
| Source Interval | 15 |
| State | NJ |
| Symbol | CELU |
| Total Cash | 6,175,000 |
| Total Cash Per Share | 0.213 |
| Total Debt | 74,713,000 |
| Total Revenue | 26,550,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.66 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.34598 |
| Two Hundred Day Average Change | -0.59088004 |
| Two Hundred Day Average Change Percent | -0.43899614 |
| Type Disp | Equity |
| Volume | 57,874 |
| Website | https://www.celularity.com |
| Zip | 7,932 |